Emerging treatments and personalised medicine for ciliopathies associated with cystic kidney disease

References

• Wilson PD. Therapeutic targets for polycystic kidney disease. Expert Opin Ther Targets. 2016;20:35–45.
   Google Scholar
• Hartung EA, Guay-Woodford LM. Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects. Pediatrics. 2014;134:e833–e845.
   Google Scholar
• Srivastava S, Sayer JA. Nephronophthisis. J Pediatr Genet. 2014;3:103–114.
   Google Scholar
• Hildebrandt F, Otto E. Cilia and centrosomes: a unifying pathogenic concept for cystic kidney disease? Nat Rev Genet. 2005;6:928–940.
   Google Scholar
• Fry AM, Leaper MJ, Bayliss R. The primary cilium. Organogenesis. 2014;10:62–68.
   Google Scholar
• Pan J, Seeger-Nukpezah T, Golemis EA. The role of the cilium in normal and abnormal cell cycles: emphasis on renal cystic pathologies. Cell Mol Life Sci. 2013;70:1849–1874.
   Google Scholar
• Goggolidou P. Wnt and planar cell polarity signaling in cystic renal disease. Organogenesis. 2014;10:86–95.
   Google Scholar
• Calvet JP. The role of calcium and cyclic AMP in PKD. In: Li X, editor. Polycystic kidney disease [Internet]. Brisbane (AU): Codon Publications; 2015. cited 2017 Aug 22. Available from: http://www.ncbi.nlm.nih.gov/books/NBK373395/
   Google Scholar
• Christensen ST, Clement CA, Satir P, et al. Primary cilia and coordination of receptor tyrosine kinase (RTK) signalling. J Pathol. 2012;226:172–184.
   Google Scholar
• Bishop GA, Berbari NF, Lewis J, et al. Type III adenylyl cyclase localizes to primary cilia throughout the adult mouse brain. J Comp Neurol. 2007;505:562–571.
   Google Scholar
• Antal MC, Bénardais K, Samama B, et al. Adenylate cyclase type III is not a ubiquitous marker for all primary cilia during development. PLoS One. 2017;12:e0170756.
   Google Scholar
• Händel M, Schulz S, Stanarius A, et al. Selective targeting of somatostatin receptor 3 to neuronal cilia. Neuroscience. 1999;89:909–926.
   Google Scholar
• Raychowdhury MK, Ramos AJ, Zhang P, et al. Vasopressin receptor-mediated functional signaling pathway in primary cilia of renal epithelial cells. Am J Physiol Renal Physiol. 2009;296:F87–F97.
   Google Scholar
• Iwanaga T, Miki T, Takahashi-Iwanaga H. Restricted expression of somatostatin receptor 3 to primary cilia in the pancreatic islets and adenohypophysis of mice. Biomed Res Tokyo Jpn. 2011;32:73–81.
   Google Scholar
• Mick DU, Rodrigues RB, Leib RD, et al. Proteomics of primary cilia by proximity labeling. Dev Cell. 2015;35:497–512.
   Google Scholar
• Boldt K, Van Reeuwijk J, Lu Q, et al. An organelle-specific protein landscape identifies novel diseases and molecular mechanisms. Nat Commun. 2016;7:11491.
   Google Scholar
• Gattone VH, Maser RL, Tian C, et al. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet. 1999;24:309–318.
   Google Scholar
• Torres VE, Wang X, Qian Q, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004;10:363–364.
   Google Scholar
• Gattone VH, Wang X, Harris PC, et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9:1323–1326.
   Google Scholar
• Wang X, Gattone V, Harris PC, et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol. 2005;16:846–851.
   Google Scholar
• Aihara M, Fujiki H, Mizuguchi H, et al. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J Pharmacol Exp Ther. 2014;349:258–267.
   Google Scholar
• Masyuk TV, Masyuk AI, Torres VE, et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate. Gastroenterology. 2007;132:1104–1116.
   Google Scholar
• Masyuk TV, Radtke BN, Stroope AJ, et al. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology. 2013;58:409–421.
   Google Scholar
• Sweeney WE, Chen Y, Nakanishi K, et al. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor11See Editorial by Grantham, p. 339. Kidney Int. 2000;57:33–40.
   Google Scholar
• Torres VE, Sweeney WE, Wang X, et al. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han: SPRDrats. Kidney Int. 2003;64:1573–1579.
   Google Scholar
• Sweeney WE, Hamahira K, Sweeney J, et al. Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int. 2003;64:1310–1319.
   Google Scholar
• Sweeney WE, Vigier RO, von Frost P, et al. Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol. 2008;19:1331–1341.
   Google Scholar
• Elliott J, Zheleznova NN, Wilson PD. c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation. Am J Physiol Cell Physiol. 2011;301:C522–C529.
   Google Scholar
• Bukanov NO, Smith LA, Klinger KW, et al. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature. 2006;444:949–952.
   Google Scholar
• Bukanov NO, Moreno SE, Natoli TA, et al. CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle Georget Tex. 2012;11:4040–4046.
   Google Scholar
• Husson H, Moreno S, Smith LA, et al. Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis. Hum Mol Genet. 2016;25:2245–2255.
   Google Scholar
• Tao Y, Kim J, Schrier RW, et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol JASN. 2005;16:46–51.
   Google Scholar
• Wahl PR, Serra AL, Le Hir M, et al. Inhibition of mTOR with sirolimus slows disease progression in Han: sPRDrats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant. 2006;21:598–604.
   Google Scholar
• Shillingford JM, Murcia NS, Larson CH, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci. 2006;103:5466–5471.
   Google Scholar
• Shillingford JM, Piontek KB, Germino GG, et al. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol. 2010;21:489–497.
   Google Scholar
• Zafar I, Ravichandran K, Belibi FA, et al. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int. 2010;78:754–761.
   Google Scholar
• Li A, Fan S, Xu Y, et al. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis. J Cell Mol Med. 2017;21:1619–1635.
   Google Scholar
• Ta MHT, Schwensen KG, Foster S, et al. Effects of TORC1 inhibition during the early and established phases of polycystic kidney disease. PLoS One. 2016;11:e0164193.
   Google Scholar
• Gattone VH, Sinders RM, Hornberger TA, et al. Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis. Kidney Int. 2009;76:178–182.
   Google Scholar
• Tobin JL, Beales PL. Restoration of renal function in zebrafish models of ciliopathies. Pediatr Nephrol. 2008;23:2095–2099.
   Google Scholar
• Wu M, Wahl PR, Le Hir M, et al. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res. 2007;30:253–259.
   Google Scholar
• Yang B, Sonawane ND, Zhao D, et al. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19:1300–1310.
   Google Scholar
• Takiar V, Nishio S, Seo-Mayer P, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A. 2011;108:2462–2467.
   Google Scholar
• Muto S, Aiba A, Saito Y, et al. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet. 2002;11:1731–1742.
   Google Scholar
• Blazer-Yost BL, Haydon J, Eggleston-Gulyas T, et al. Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease. PPAR Res. 2010;2010:274376.
   Google Scholar
• Yoshihara D, Kurahashi H, Morita M, et al. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol. 2011;300:F465–F474.
   Google Scholar
• Flaig SM, Gattone VH, Blazer-Yost BL. Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor γ agonists. J Transl Intern Med. 2016;4:118–126.
   Google Scholar
• Raphael KL, Strait KA, Stricklett PK, et al. Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease. Am J Nephrol. 2009;30:468–473.
   Google Scholar
• Dai B, Liu Y, Mei C, et al. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han: sPRDrats. Clin Sci Lond Engl. 1979;2010(119):323–333.
   Google Scholar
• Cao Y, Semanchik N, Lee SH, et al. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. Proc Natl Acad Sci. 2009;106:21819–21824.
   Google Scholar
• Xia S, Li X, Johnson T, et al. Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts. Development. 2010;137:1075–1084.
   Google Scholar
• Fan LX, Li X, Magenheimer B, et al. Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation. Kidney Int. 2012;81:76–85.
   Google Scholar
• Cebotaru L, Liu Q, Yanda MK, et al. Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease. Kidney Int. 2016;90:90–99.
   Google Scholar
• Zhou X, Fan LX, Sweeney WE, et al. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. J Clin Invest. 2013;123:3084–3098.
   Google Scholar
• Klawitter J, Zafar I, Klawitter J, et al. Effects of lovastatin treatment on the metabolic distributions in the Han:sPRDrat model of polycystic kidney disease. BMC Nephrol. 2013;14:165.
   Google Scholar
• Yamaguchi T, Nagao S, Kasahara M, et al. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis. 1997;30:703–709.
   Google Scholar
• Smith LA, Bukanov NO, Husson H, et al. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol. 2006;17:2821–2831.
   Google Scholar
• Starremans PG, Li X, Finnerty PE, et al. A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5′ end of Pkd1. Kidney Int. 2008;73:1394–1405.
   Google Scholar
• Hopp K, Ward CJ, Hommerding CJ, et al. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest. 2012;122:4257–4273.
   Google Scholar
• Wallace DP. Cyclic AMP-mediated cyst expansion. Biochim Biophys Acta. 2011;1812:1291–1300.
   Google Scholar
• Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol. 2014;25:18–32.
   Google Scholar
• Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–2418.
   Google Scholar
• Gansevoort RT, Arici M, Benzing T, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016;31:337–348.
   Google Scholar
• Winkler SN, Torikai S, Levine BS, et al. Effect of somatostatin on vasopressin-induced antidiuresis and renal cyclic AMP of rats. Miner Electrolyte Metab. 1982;7:8–14.
   Google Scholar
• Friedlander G, Amiel C. Somatostatin and alpha 2-adrenergic agonists selectively inhibit vasopressin-induced cyclic AMP accumulation in MDCK cells. FEBS Lett. 1986;198:38–42.
   Google Scholar
• Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 2005;68:206–216.
   Google Scholar
• Ghosh AK, Hurd T, Hildebrandt F. 3D spheroid defects in NPHP knockdown cells are rescued by the somatostatin receptor agonist octreotide. Am J Physiol Ren Physiol. 2012;303:F1225–F1229.
   Google Scholar
• Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol JASN. 2010;21:1052–1061.
   Google Scholar
• van Keimpema L, Nevens F, Vanslembrouck R, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009;137:1661-1668-2.
   Google Scholar
• Caroli A, Perico N, Perna A, et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet. 2013;382:1485–1495.
   Google Scholar
• Myint TM, Rangan GK, Webster AC. Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials: ADPKD meta-analysis. Nephrology. 2014;19:217–226.
   Google Scholar
• Du J, Wilson PD. Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD. Am J Physiol. 1995;269:C487–495.
   Google Scholar
• Orellana SA, Sweeney WE, Neff CD, et al. Epidermal growth factor receptor expression is abnormal in murine polycystic kidney. Kidney Int. 1995;47:490–499.
   Google Scholar
• Nakanishi K, Sweeney W, Avner ED. Segment-specific c-ErbB2 expression in human autosomal recessive polycystic kidney disease. J Am Soc Nephrol JASN. 2001;12:379–384.
   Google Scholar
• Pugh JL, Sweeney WE, Avner ED. Tyrosine kinase activity of the EGF receptor in murine metanephric organ culture. Kidney Int. 1995;47:774–781.
   Google Scholar
• Sweeney WE, Avner ED. Functional activity of epidermal growth factor receptors in autosomal recessive polycystic kidney disease. Am J Physiol Ren Physiol. 1998;275:F387–F394.
   Google Scholar
• Ye M, Grant M, Sharma M, et al. Cyst fluid from human autosomal dominant polycystic kidneys promotes cyst formation and expansion by renal epithelial cells in vitro. J Am Soc Nephrol JASN. 1992;3:984–994.
   Google Scholar
• Rohatgi R, Zavilowitz B, Vergara M, et al. Cyst fluid composition in human autosomal recessive polycystic kidney disease. Pediatr Nephrol Berl Ger. 2005;20:552–553.
   Google Scholar
• Zheleznova NN, Wilson PD, Staruschenko A. Epidermal growth factor-mediated proliferation and sodium transport in normal and PKD epithelial cells. Biochim Biophys Acta. 2011;1812:1301–1313.
   Google Scholar
• Torres VE, Sweeney WE, Wang X, et al. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats. Kidney Int. 2004;66:1766–1773.
   Google Scholar
• Yamaguchi T, Pelling JC, Ramaswamy NT, et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway1. Kidney Int. 2000;57:1460–1471.
   Google Scholar
• Yamaguchi T, Nagao S, Wallace DP, et al. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int. 2003;63:1983–1994.
   Google Scholar
• Yamaguchi T, Wallace DP, Magenheimer BS, et al. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem. 2004;279:40419–40430.
   Google Scholar
• Yamaguchi T, Reif GA, Calvet JP, et al. Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol. 2010;299:F944–F951.
   Google Scholar
• Rastogi A, Rosner MH, Barash I, et al. Tyrosine kinase inhibitor tesevatinib for patients with autosomal dominant polycystic kidney disease. J Am Soc  Neph. 2015;26:830A.
   Google Scholar
• Choi HJC, Lin J-R, Vannier J-B, et al. NEK8 links the ATR-regulated replication stress response and S phase CDK activity to renal ciliopathies. Mol Cell. 2013;51:423–439.
   Google Scholar
• Slaats GG, Saldivar JC, Bacal J, et al. DNA replication stress underlies renal phenotypes in CEP290-associated Joubert syndrome. J Clin Invest. 2015;125:3657–3666.
   Google Scholar
• Senderowicz AM. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs. 1999;17:313–320.
   Google Scholar
• Schang LM, Rosenberg A, Schaffer PA. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. J Virol. 2000;74:2107–2120.
   Google Scholar
• Schang LM, Bantly A, Knockaert M, et al. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. J Virol. 2002;76:7874–7882.
   Google Scholar
• Xu H, Yu S, Liu Q, et al. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. J Hematol Oncol. 2017;10:97.
   Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130–146.
   Google Scholar
• Wilson PD. Polycystic kidney disease. N Engl J Med. 2004;350:151–164.
   Google Scholar
• Siroky BJ, Towbin AJ, Trout AT, et al. Improvement in renal cystic disease of tuberous sclerosis complex after treatment with mammalian target of rapamycin inhibitor. J Pediatr. 2017;187:318–322.e2.
   Google Scholar
• Gao X, Zhang Y, Arrazola P, et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol. 2002;4:699–704.
   Google Scholar
• Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4:648–657.
   Google Scholar
• Tee AR, Fingar DC, Manning BD, et al. Tuberous sclerosis complex-1 and −2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A. 2002;99:13571–13576.
   Google Scholar
• Hartman TR, Liu D, Zilfou JT, et al. The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway. Hum Mol Genet. 2009;18:151–163.
   Google Scholar
• Boletta A. Emerging evidence of a link between the polycystins and the mTOR pathways. PathoGenetics. 2009;2:6.
   Google Scholar
• Pema M, Drusian L, Chiaravalli M, et al. mTORC1-mediated inhibition of polycystin-1 expression drives renal cyst formation in tuberous sclerosis complex. Nat Commun 2016;7:ncomms10786.
   Google Scholar
• Distefano G, Boca M, Rowe I, et al. Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol. 2009;29:2359–2371.
   Google Scholar
• Zafar I, Belibi FA, He Z, et al. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant. 2009;24:2349–2353.
   Google Scholar
• Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363:830–840.
   Google Scholar
• Grantham JJ, Bennett WM, Perrone RD. mTOR inhibitors and autosomal dominant polycystic kidney disease. N Engl J Med. 2011;364:286–289.
   Google Scholar
• Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363:820–829.
   Google Scholar
• Jardine MJ, Liyanage T, Buxton E, et al. mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open. Nephrol Dial Trans Off Publ Eur Dial Transpl Assoc Eur Ren Assoc. 2013;28:242–244.
   Google Scholar
• Perico N, Antiga L, Caroli A, et al. Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol JASN. 2010;21:1031–1040.
   Google Scholar
• Belibi F, Ravichandran K, Zafar I, et al. mTORC1/2 and rapamycin in female Han: sPRDrats with polycystic kidney disease. Am J Physiol Renal Physiol. 2011;300:F236–F244.
   Google Scholar
• Ravichandran K, Zafar I, He Z, et al. An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2. Hum Mol Genet. 2014;23:4919–4931.
   Google Scholar
• O’Sullivan DA, Torres VE, Gabow PA, et al. Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis Off J Natl Kidney Found. 1998;32:976–983.
   Google Scholar
• Xu N, Glockner JF, Rossetti S, et al. Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis. J Nephrol. 2006;19:529–534.
   Google Scholar
• Tradtrantip L, Sonawane ND, Namkung W, et al. Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model. J Med Chem. 2009;52:6447–6455.
   Google Scholar
• Nofziger C, Brown KK, Smith CD, et al. PPARγ agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line. Am J Physiol Ren Physiol. 2009;297:F55–F62.
   Google Scholar
• Home P. Safety of PPAR agonists. Diabetes Care. 2011;34:S215–S219.
   Google Scholar
• van Dijk MA, Kamper AM, van Veen S, et al. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Trans Off Publ Eur Dial Transpl Assoc Eur Ren Assoc. 2001;16:2152–2157.
   Google Scholar
• Cadnapaphornchai MA, George DM, McFann K, et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol CJASN. 2014;9:889–896.
   Google Scholar
• Ruiz-Perez VL, Blair HJ, Rodriguez-Andres ME, et al. Evc is a positive mediator of Ihh-regulated bone growth that localises at the base of chondrocyte cilia. Dev Camb Engl. 2007;134:2903–2912.
   Google Scholar
• Aguilar A, Meunier A, Strehl L, et al. Analysis of human samples reveals impaired SHH-dependent cerebellar development in Joubert syndrome/Meckel syndrome. Proc Natl Acad Sci U S A. 2012;109:16951–16956.
   Google Scholar
• Attanasio M, Uhlenhaut NH, Sousa VH, et al. Loss of GLIS2 causes nephronophthisis in humans and mice by increased apoptosis and fibrosis. Nat Genet. 2007;39:1018–1024.
   Google Scholar
• Hynes AM, Giles RH, Srivastava S, et al. Murine Joubert syndrome reveals Hedgehog signaling defects as a potential therapeutic target for nephronophthisis. Proc Natl Acad Sci. 2014;111:9893–9898.
   Google Scholar
• Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6:114–118.
   Google Scholar
• Ehret T, Torelli F, Klotz C, et al. Translational rodent models for research on parasitic protozoa - a review of confounders and possibilities. Front Cell Infect Microbiol. 2017;7:238.
   Google Scholar
• Ortiz A, Sanchez-Niño MD, Izquierdo MC, et al. Translational value of animal models of kidney failure. Eur J Pharmacol. 2015;759:205–220.
   Google Scholar
• Harris PC, Torres VE. Polycystic kidney disease, autosomal dominant. In: Pagon RA, Adam MP, Ardinger HH, et al. editors. GeneReviews(®) [Internet]. Seattle (WA): University of Washington, Seattle; 1993. cited 2017 Aug 22. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1246/
   Google Scholar
• Braun DA, Hildebrandt F. Ciliopathies. Cold Spring Harb Perspect Biol. 2017;9:a028191.
   Google Scholar
• Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–872.
   Google Scholar
• Zhou T, Benda C, Dunzinger S, et al. Generation of human induced pluripotent stem cells from urine samples. Nat Protoc. 2012;7:2080–2089.
   Google Scholar
• Shi L, Cui Y, Luan J, et al. Urine-derived induced pluripotent stem cells as a modeling tool to study rare human diseases. Intractable Rare Dis Res. 2016;5:192–201.
   Google Scholar
• El Hokayem J, Cukier HN, Dykxhoorn DM. Blood derived induced pluripotent stem cells (iPSCs): benefits, challenges and the road ahead. J Alzheimers Dis Park. 2016;6:275.
   Google Scholar
• Song B, Smink AM, Jones CV, et al. The directed differentiation of human iPS cells into kidney podocytes. PloS One. 2012;7:e46453.
   Google Scholar
• Xia Y, Nivet E, Sancho-Martinez I, et al. Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like cells. Nat Cell Biol. 2013;15:1507–1515.
   Google Scholar
• Morizane R, Monkawa T, Fujii S, et al. Kidney specific protein-positive cells derived from embryonic stem cells reproduce tubular structures in vitro and differentiate into renal tubular cells. PloS One. 2014;8:e64843.
   Google Scholar
• Takasato M, Er PX, Becroft M, et al. Directing human embryonic stem cell differentiation towards a renal lineage generates a self-organizing kidney. Nat Cell Biol. 2014;16:118–126.
   Google Scholar
• Lam AQ, Freedman BS, Morizane R, et al. Rapid and efficient differentiation of human pluripotent stem cells into intermediate mesoderm that forms tubules expressing kidney proximal tubular markers. J Am Soc Nephrol JASN. 2014;25:1211–1225.
   Google Scholar
• Ciampi O, Iacone R, Longaretti L, et al. Generation of functional podocytes from human induced pluripotent stem cells. Stem Cell Res. 2016;17:130–139.
   Google Scholar
• Takasato M, Er PX, Chiu HS, et al. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature. 2015;526:564–568.
   Google Scholar
• Taguchi A, Kaku Y, Ohmori T, et al. Redefining the in vivo origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells. Cell Stem Cell. 2014;14:53–67.
   Google Scholar
• Morizane R, Lam AQ, Freedman BS, et al. Nephron organoids derived from human pluripotent stem cells model kidney development and injury. Nat Biotechnol. 2015;33:1193–1200.
   Google Scholar
• Freedman BS, Brooks CR, Lam AQ, et al. Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. Nat Commun. 2015;6:8715.
   Google Scholar
• Ginn SL, Alexander IE, Edelstein ML, et al. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med. 2013;15:65–77.
   Google Scholar
• Heikkilä P, Tibell A, Morita T, et al. Adenovirus-mediated transfer of type IV collagen alpha5 chain cDNA into swine kidney in vivo: deposition of the protein into the glomerular basement membrane. Gene Ther. 2001;8:882–890.
   Google Scholar
• Park J, Murray GJ, Limaye A, et al. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. Proc Natl Acad Sci U S A. 2003;100:3450–3454.
   Google Scholar
• Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346:1258096.
   Google Scholar
• Yin H, Xue W, Chen S, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. 2014;32:551–553.
   Google Scholar
• Long C, Amoasii L, Mireault AA, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016;351:400–403.
   Google Scholar
• Nelson CE, Hakim CH, Ousterout DG, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016;351:403–407.
   Google Scholar
• Tabebordbar M, Zhu K, Cheng JKW, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. 2016;351:407–411.
   Google Scholar
• Xu L, Park KH, Zhao L, et al. CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice. Mol Ther J Am Soc Gene Ther. 2016;24:564–569.
   Google Scholar
• Yang Y, Wang L, Bell P, et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol. 2016;34:334–338.
   Google Scholar
• Yin H, Song C-Q, Dorkin JR, et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol. 2016;34:328–333.
   Google Scholar
• Ohmori T, Nagao Y, Mizukami H, et al. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice. Sci Rep. 2017;7:4159.
   Google Scholar
• Yin H, Kauffman KJ, Anderson DG. Delivery technologies for genome editing. Nat Rev Drug Discov. 2017;16:387–399.
   Google Scholar
• Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011;378:595–605.
   Google Scholar
• Gerard X, Perrault I, Hanein S, et al. AON-mediated exon skipping restores ciliation in fibroblasts harboring the common Leber congenital amaurosis CEP290 mutation. Mol Ther Nucleic Acids. 2012;1:e29.
   Google Scholar
• Sayer JA, Otto EA, O’Toole JF, et al. The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4. Nat Genet. 2006;38:674–681.
   Google Scholar
• Valente EM, Silhavy JL, Brancati F, et al. Mutations in CEP290, which encodes a centrosomal protein, cause pleiotropic forms of Joubert syndrome. Nat Genet. 2006;38:623–625.
   Google Scholar
• Coppieters F, Lefever S, Leroy BP, et al. CEP290, a gene with many faces: mutation overview and presentation of CEP290base. Hum Mutat. 2010;31:1097–1108.
   Google Scholar
• Molinari E, Srivastava S, Sayer JA, et al. From disease modelling to personalised therapy in patients with CEP290 mutations. F1000Research. 2017;6:669.
   Google Scholar
• Peces R, Peces C, Coto E, et al. Bilineal inheritance of type 1 autosomal dominant polycystic kidney disease (ADPKD) and recurrent fetal loss. NDT Plus. 2008;1:289–291.
   Google Scholar
• Pei Y, Paterson AD, Wang KR, et al. Bilineal disease and trans-heterozygotes in autosomal dominant polycystic kidney disease. Am J Hum Genet. 2001;68:355–363.
   Google Scholar
• Wu X, Gao H, Pasupathy S, et al. Systemic administration of naked DNA with targeting specificity to mammalian kidneys. Gene Ther. 2005;12:477–486.
   Google Scholar
• Rocca CJ, Ur SN, Harrison F, et al. rAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: conclusion of a comparative study. Gene Ther. 2014;21:618–628.
   Google Scholar
• Oroojalian F, Rezayan AH, Mehrnejad F, et al. Efficient megalin targeted delivery to renal proximal tubular cells mediated by modified-polymyxin B-polyethylenimine based nano-gene-carriers. Mater Sci Eng C. 2017;79:770–782.
   Google Scholar
• Wolf MTF. Nephronophthisis and related syndromes. Curr Opin Pediatr. 2015;27:201–211.
   Google Scholar
• Lohmann K, Klein C. Next generation sequencing and the future of genetic diagnosis. Neurother J Am Soc Exp Neurother. 2014;11:699–707.
   Google Scholar
• Besse W, Dong K, Choi J, et al. Isolated polycystic liver disease genes define effectors of polycystin-1 function. J Clin Invest. 2017;127:1772–1785.
   Google Scholar
• Zarrinpar A, Lee D-K, Silva A, et al. Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform. Sci Transl Med. 2016;8:333ra49.
   Google Scholar